Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Nanomedicine (Lond) ; 17(10): 717-739, 2022 04.
Artigo em Inglês | MEDLINE | ID: mdl-35481356

RESUMO

Background: Yessotoxin (YTX), a marine-derived drug, was encapsulated in PEGylated pH-sensitive nanoliposomes, covalently functionalized (strategy I) with SDF-1α and by nonspecific adsorption (strategy II), to actively target chemokine receptor CXCR-4. Methods: Cytotoxicity to normal human epithelial cells (HK-2) and prostate (PC-3) and breast (MCF-7) adenocarcinoma models, with different expression levels of CXCR-4, were tested. Results: Strategy II exerted the highest cytotoxicity toward cancer cells while protecting normal epithelia. Acid pH-induced fusion of nanoliposomes seemed to serve as a primary route of entry into MCF-7 cells but PC-3 data support an endocytic pathway for their internalization. Conclusion: This work describes an innovative hallmark in the current marine drug clinical pipeline, as the developed nanoliposomes are promising candidates in the design of groundbreaking marine flora-derived anticancer nanoagents.


Assuntos
Neoplasias , Oxocinas , Quimiocina CXCL12/metabolismo , Humanos , Concentração de Íons de Hidrogênio , Células MCF-7 , Masculino , Venenos de Moluscos , Neoplasias/tratamento farmacológico , Receptores CXCR4
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...